# Oral CBD May Help Lower Blood Pressure, New Review Finds > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/oral-cbd-may-help-lower-blood-pressure-new-review-finds/ > **Published:** 2026-06-20T16:25:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:51:13-04:00 > **Clinical Summary:** Systemic review of CBD blood pressure effects. Learn what clinicians need to know about cannabidiol for hypertension management and cardiovascular safety. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CBDResearchSafetyAnxietyCancerPainDosing Why This Matters Clinicians should be aware that CBD may offer a non-pharmacological option for blood pressure management in patients who are intolerant of or resistant to conventional antihypertensives, though more rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are needed to establish optimal dosing and long-term safety. For patients with cancer-related symptoms, evidence that [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) extracts benefit approximately 50% of users could inform shared decision-making discussions about symptom management, particularly for pain, nausea, and appetite loss when standard treatments are inadequate. Given the growing patient interest in [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/), clinicians need current evidence to counsel patients appropriately about potential benefits and risks rather than defaulting to dismissal or unqualified endorsement. Clinical Summary A recent clinical review suggests that oral cannabidiol (CBD) may have modest blood pressure-lowering effects, potentially offering an adjunctive option for patients with hypertension seeking alternative or complementary therapies. The mechanism appears related to CBD’s anxiolytic and vasodilatory properties, though the evidence base remains limited with most studies involving small sample sizes and short follow-up periods. For clinicians considering CBD in hypertensive patients, current evidence is insufficient to recommend it as monotherapy, but it may warrant discussion as a complementary approach in select patients who are already on standard antihypertensive regimens. The review highlights important gaps in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), including the lack of standardized dosing, formulations, and long-term safety data specific to cardiovascular outcomes. Clinicians should counsel patients that [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) remain largely unregulated, quality and potency vary widely across commercial preparations, and potential drug interactions with antihypertensive medications warrant careful monitoring. Patients interested in oral CBD for blood pressure management should consult their physician before use and should not discontinue proven antihypertensive medications in favor of CBD alone. Dr. Caplan’s Take “The early signals here are worth watching, but we need to be cautious about the gap between what these reviews suggest and what we can confidently tell patients—the studies vary considerably in design and patient populations, so I’m tracking this literature closely rather than making it standard practice right now.” Clinical Perspective 💊 While emerging evidence suggests cannabidiol may have modest blood pressure-lowering effects in some patients, healthcare providers should recognize that most existing trials are small, short-term, and often sponsored by industry stakeholders, limiting generalizability to diverse clinical populations. The heterogeneity in CBD formulations, dosing regimens, and patient populations across studies makes it difficult to establish clear clinical dosing guidelines or predict which patients might benefit most. Current evidence is insufficient to recommend CBD as a first-line or replacement therapy for hypertension, particularly given the well-established efficacy and safety profiles of conventional antihypertensives. Providers should remain cautious about potential drug interactions (especially with CYP3A4 substrates) and the variable regulation of [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/), which may contain inconsistent cannabinoid concentrations or unlabeled contaminants. If patients express interest in CBD for blood pressure management, a shared decision-making approach 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Oral%20CBD%20May%20Help%20Lower%20Blood%20Pressure%2C%20New%20Review%20Finds%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D60869)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D60869)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Oral%20CBD%20May%20Help%20Lower%20Blood%20Pressure%2C%20New%20Review%20Finds%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D60869)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - In the Mix: 37 More Articles — June 20, 2026 - [Best THC Gummies for Sleep in 2026: Top THC Sleep Gummies Reviewed for Deep, Restful Nights](https://cedclinic.com/cbd-gummies-male-enhancement-marketing-concerns/) - [Do CBD Gummies Lower Blood Pressure? Research, Benefits, and Safety Tips – piper](https://cedclinic.com/cbd-gummies-male-enhancement-marketing-concerns/) 📰 Source: [https://themarijuanaherald.com/2026/06/oral-cbd-may-help-lower-blood-pressure-new-review-finds/](https://themarijuanaherald.com/2026/06/oral-cbd-may-help-lower-blood-pressure-new-review-finds/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).